Holen Sie sich die Stockscreener-App
32.90
6.33%
1.96
Vorhandelsmarkt:
32.80
-0.10
-0.30%
Schlusskurs vom Vortag:
$30.94
Offen:
$31.33
24-Stunden-Volumen:
3.22M
Relative Volume:
0.89
Marktkapitalisierung:
$5.36B
Einnahmen:
$56.99M
Nettoeinkommen (Verlust:
$-107.23M
KGV:
-40.13
EPS:
-0.8199
Netto-Cashflow:
$-142.55M
1W Leistung:
+6.37%
1M Leistung:
+60.02%
6M Leistung:
+260.75%
1J Leistung:
+601.49%
1-Tages-Spanne:
$30.75
$33.00
1-Wochen-Bereich:
$28.07
$33.00
52-Wochen-Spanne:
$4.40
$33.00
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
32.90 | 5.36B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-23 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Why is Tango Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66 - Moomoo
Tango Therapeutics prices upsized $600M public offering at $30/share - MSN
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
[144] Tango Therapeutics, Inc. SEC Filing - Stock Titan
Tango Therapeutics Announces Major Underwritten Equity Offering - TipRanks
Tango Therapeutics Prices $600 Million Stock Offering - Moomoo
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66 - Moomoo
Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted - TradingView
Tango Therapeutics (NASDAQ: TNGX) prices $566.5M stock and warrant offering - Stock Titan
Tango Therapeutics (TNGX) raises ~$566.5M via 18.17M shares and pre-funded warrants - Stock Titan
Insider sale notice — TNGX (NASDAQ:TNGX) reports planned share sales - Stock Titan
Tango Therapeutics stock price target raised to $66 by H.C. Wainwright on trial data - Investing.com
Tango Therapeutics stock hits all-time high at 32.69 USD By Investing.com - Investing.com India
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year - Yahoo Finance
Tango Therapeutics prices $600M upsized public offering - scanx.trade
Tango Therapeutics prices $600 million stock offering - Investing.com India
Tango Therapeutics prices $600 million stock offering By Investing.com - Investing.com India
Tango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering - The Manila Times
Tango Therapeutics Expects Gross Proceeds of About $600M From Offering >TNGX - Moomoo
Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates - Stocktwits
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Tango Therapeutics launches $500 million stock offering By Investing.com - Investing.com Australia
Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite (TNGX) - Seeking Alpha
Tango Therapeutics stock rockets 53% on pancreatic cancer data - grafa.com
TNGX Maintained by HC Wainwright & Co. -- Price Target Raised to $66 - GuruFocus
Tango Therapeutics stock hits all-time high at 32.69 USD - Investing.com
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results - Yahoo Finance
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $42 - GuruFocus
Tango Therapeutics stock surges on pancreatic cancer trial data - qz.com
Tango Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results - Barchart.com
Canaccord raises Tango Therapeutics stock price target on drug combo By Investing.com - Investing.com Nigeria
Canaccord raises Tango Therapeutics stock price target on drug combo - Investing.com
B. Riley Raises Price Target on Tango Therapeutics to $35 From $21, Keeps Buy Rating - marketscreener.com
Tango Therapeutics Stock Soars 53% After Pancreatic Cancer Trial Stuns Wall Street - TIKR.com
Tango Therapeutics Shares Surge 53% on Promising Pancreatic Cancer Trial Data - International Business Times Australia
Why Tango Therapeutics (TNGX) Is Up 33.9% After Highlighting Pancreatic Cancer Pipeline Data Prospects - simplywall.st
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are - Benzinga
Tango Therapeutics stock soars on promising pancreatic cancer data - CryptoRank
TNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’ - MSN
Tango’s PRMT5 inhibitor adds to daraxonrasib activity in pancreatic cancer - BioCentury
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36.91, Implies 83% Upside - TradingView
Tango Therapeutics (TNGX) director receives 4,000 RSUs and 25,000-share option grant - Stock Titan
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):